Financhill
Back

Royalty Pharma PLC Quote, Financials, Valuation and Earnings

Royalty Pharma PLC Price Quote

$28.39
-0.37 (-1.29%)
(Updated: May 3, 2024 at 6:55 PM ET)

Royalty Pharma PLC Key Stats

Sell
32
Royalty Pharma PLC (RPRX) is a Sell

Day range:
$28.24 - $28.99
52-week range:
$25.92 - $35.70
Dividend yield:
2.82%
P/E ratio:
11.37
P/S ratio:
7.36
P/B ratio:
1.97%

Volume:
3.9M
Avg. volume:
2.6M
1-year change:
-17.97%
Market cap:
$12.8B
Revenue:
$2.4B
EPS:
$2.52

How Much Does Royalty Pharma PLC Make?

Is Royalty Pharma PLC Growing As A Company?

  • What Is Royalty Pharma PLC's Growth Rate Quarterly?
    Quarterly YoY revenue growth is 0.05%
  • What Is Royalty Pharma PLC's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Royalty Pharma PLC Stock Price Performance

What Is Royalty Pharma PLC 52-Week High & Low?

Royalty Pharma PLC Price To Free Cash Flow

Is It Risky To Buy Royalty Pharma PLC?

Is Royalty Pharma PLC Cash Flow Positive?

  • What Is RPRX Cash Flow From Operations?
    Cash flow from operations (TTM) is $3B
  • What Is Royalty Pharma PLC’s Cash Flow From Financing?
    Cash flow from financing (TTM) is -$2.1B
  • What Is Royalty Pharma PLC’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$2.1B

Royalty Pharma PLC Return On Invested Capital

  • Is Management Doing A Good Job?
    RPRX return on invested capital is 6.88%
  • What Is Royalty Pharma PLC Return On Assets?
    ROA measures how assets are converting to revenues and is 6.82%
  • What Is RPRX Return On Equity?
    ROE is a measure of profitability and is 11.62%

Royalty Pharma PLC Earnings Date & Stock Price

Royalty Pharma PLC Competitors

  • Who Are Royalty Pharma PLC's Competitors?
    Below is a list of companies who compete with Royalty Pharma PLC or are related in some way:
    • Amphastar Pharmaceuticals Inc (AMPH)
    • Maravai LifeSciences Holdings Inc (MRVI)
    • Pacira BioSciences Inc (PCRX)
    • Viatris Inc (VTRS)
    • Walgreens Boots Alliance Inc (WBA)

Royalty Pharma PLC Dividend Yield

Royalty Pharma PLC Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 51.7%
Revenue: 5.36% -11.64%

Analyst Recommendations

Buy Recommendations: 5
Hold Recommendations: 1
Sell Recommendations: 0
Price Target: 45.88
Upside from Last Price: 59.51%

Major Shareholders

  • How many RPRX shares are owned by institutional investors?
    483.6M RPRX shares are owned by institutional investors
  • How many RPRX shares are owned by insiders?
    824.6K RPRX shares are owned by insiders